Fungi drug resistance

Significant drug interactions include cyclosporins (increased cyclosporine levels), phenytoin, rifampin, and rifabutin (decreased voriconazole levels). Because of its low toxicity profile, this drug may gain importance in the chronic treatment of infections with invasive dimorphic fungi and resistant Candida spp. 

Drug therapy, particularly with broad spectrum antimicrobials or combinations of agents, can lead to alterations of the normal microbial flora of the upper respiratory, intestinal and genitourinary tracts, permitting the overgrowth of opportunistic organisms, especially fungi or resistant bacteria. These infections are often difficult to treat. 

Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998 36(Suppl l) 119-28. Viviani MA. Flucytosine—what is its future J Antimicrob Chemother 1995 35(2) 241. ... 

Parent strains of certain bacteria, e.g., antibiotic-resistant or antitubercular-drug-resistant strains, can be differentiated from nonresistant substrains. The spores of phytopathogenic fungi can be differentiated by means of their spectra. Viruses can also be differentiated. 

---